Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;110(10):2481-2486.
doi: 10.3324/haematol.2024.286825. Epub 2025 Apr 30.

Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

Gregorio Barilà  1 , Angela Grassi  2 , Concetta Conticello  3 , Roberto Mina  4 , Chiara Marcon  5 , Francesca Fazio  6 , Claudio Salvatore Cartia  7 , Martina Tinelli  8 , Maria Livia Del Giudice  9 , Sofia Pilerci  10 , Angelo Belotti  11 , Anna Pascarella  12 , Mariantonietta Tafuri  13 , Serena Rocchi  14 , Katia Mancuso  14 , Nicola Sgherza  15 , Giuseppe Mele  16 , Edoardo Scomazzon  1 , Massimo Gentile  17 , Marika Porrazzo  18 , Norbert Pescosta  19 , Anna Furlan  20 , Massimiliano Arangio Febbo  21 , Cristina Clissa  8 , Andrea Casson  4 , Rossella Ribolla  11 , Antonio Maroccia  12 , Chiara Lisi  6 , Enrica Antonia Martino  22 , Ombretta Annibali  13 , Gabriele Buda  9 , Elisabetta Antonioli  10 , Silvia Mangiacavalli  7 , Alberto Tosetto  1 , Pellegrino Musto  23 , Francesca Gay  24 , Elena Zamagni  14 , Maria Teresa Petrucci  6 , Francesco Di Raimondo  3 , Francesca Patriarca  5 , Renato Zambello  25
Affiliations

Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

Gregorio Barilà et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival and overall survival of patients receiving lenalidomide maintenance treatment. (A-D) Kaplan-Meier curves showing the progression-free survival of patients who received lenalidomide maintenance according to cytogenetic status (A), the number of high-risk cytogenetic abnormalities (B), the number of autologous stem cell transplants (C) and the lenalidomide schedule (D). (E-H) Kaplan-Meier curves showing the overall survival of patients who received lenalidomide maintenance according to cytogenetic status (E), the number of high-risk cytogenetic abnormalities (F), the number of autologous stem cell transplants (G) and the lenalidomide schedule (H). PFS: progression-free survival; SR: standard risk; HR: high risk; OS: overall survival; ASCT: autologous stem cell transplant.
See this image and copyright information in PMC

References

    1. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528. - PMC - PubMed
    1. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29-38. - PubMed
    1. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085. - PubMed
    1. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289. - PMC - PubMed
    1. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/ HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456-e468. - PubMed

LinkOut - more resources